European regulators dealt Merck KGaA (MRCG.DE) another blow by sticking with their recommendation against what once was the group's biggest pipeline hope, multiple sclerosis (MS) pill cladribine.
The European Union's drugs watchdog, which had already recommended against cladribine in September, prompting an appeal from Merck, still found that the benefits of cladribine tablets did not outweigh its risks, Merck said on Friday.
via reuters.com
No comments:
Post a Comment